ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours.

BACKGROUND: Panobinostat treatment has been shown to terminally differentiate malignant rhabdoid tumours (MRT) and atypical teratoid rhabdoid tumours (ATRT) in pre-clinical models. We report results of the open label, phase II study of oral panobinostat in patients with newly diagnosed or relapsed M...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Paul, Desai, Jayesh, Waldeck, Kelly, Cain, Jason, Gottardo, Nicholas, Strong, Robyn, Kinross, Kathryn, Carr, Michelle, Jones, Janelle, Wong, Lily, Ziegler, David, Hansford, Jordan, Michael, Michael, Ashley, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Atypical Teratoid Rhabdoid Tumor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164747/
http://dx.doi.org/10.1093/neuonc/noac079.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164747/
http://dx.doi.org/10.1093/neuonc/noac079.016

Ejemplares similares